
[Proposal Status/Commentary](#)

After a standard is proposed in *Pharmacopeial Forum* (*PF*) for public comment, the assigned Expert Committee reviews the comments and determines whether to approve the standard as a Revision, defer or cancel the standard. USP posts the lists of Revisions, Deferrals, Cancellations, and Commentary for each Issue of *USP–NF*.

- Revisions are items that have been proposed in *PF*, were approved by the assigned Expert Committee, and will appear in the noted publication. These items will have corresponding Commentary (see below).
- Deferrals are items that have been proposed in *PF* but are not yet approved by an Expert Committee. Items that have been deferred can be approved and published in a subsequent Issue of *USP–NF*. Some deferrals are later canceled.
- Cancellations are items that have been proposed in *PF* but will not move forward to ballot and subsequent publication. Canceled items may be re-proposed in a future *PF*.

Commentary is a summary of comments received and the assigned Expert Committee's responses. Commentary is published for Revisions only. In cases where proposals have been re-published in *PF*, only comments from the most recent *PF* publication are included in Commentary. Revisions, Deferrals, and Cancellations generally are posted prior to publication in *USP–NF Online*. Commentary is posted the same day the official text is published in *USP–NF Online*.

[2020-2024 Cumulative List of USP–NF Revisions](#) (updated 30-Aug-2024)

The Cumulative List of *USP–NF* Revisions provides updated information on all items approved, deferred, or cancelled during the 2020-2025 Cycle. Cumulative List from 2015-2020 cycle can be found [here](#).

USP-NF 2025, Issue 1

- [Deferrals](#) (posted 23-Jul-2024)

-
- [Cancellations](#) (posted 23-Jul-2024)
 - [Revisions](#) (posted 23-Jul-2024)

USP-NF 2024, Issue 3

- [Deferrals](#) (posted 26-Apr-2024)
- [Cancellations](#) (posted 26-Apr-2024)
- [Revisions](#) (posted 26-Apr-2024)
- [Commentary](#) (posted 03-Jun-2024)

USP-NF 2024, Issue 2 (currently official)

- [Deferrals](#) (posted 27-Dec-2023)
- [Cancellations](#) (posted 27-Dec-2023)
- [Revisions](#) (posted 27-Dec-2023)
- [Commentary](#) (posted 01-Feb-2024)

USP-NF 2024, Issue 1

- [Deferrals](#) (posted 29-Sep-2023)
- [Cancellations](#) (posted 29-Sep-2023)
- [Revisions](#) (posted 29-Sep-2023)
- [Commentary](#) (posted 01-Nov-2023; updated 26-Dec-2023)
- [Monographs appearing in redesign format](#) (posted 27-Dec-2023)

USP-NF 2023, Issue 3

- [Deferrals](#) (posted 28-Apr-2023)
- [Cancellations](#) (posted 28-Apr-2023)
- [Revisions](#) (posted 28-Apr-2023)
- [Commentary](#) (posted 01-Jun-2023)

Previous USP-NF Issues

Expand/collapse list

[USP-NF 2023](#)

[USP-NF 2022](#)

[USP-NF 2021](#)

[USP 43-NF 38](#)

[USP 42-NF 37](#)

[USP 41-NF 36](#)

[USP 40-NF 35](#)

[USP 39-NF 34](#)

[USP 38-NF 33](#)

[USP 37-NF 32](#)

[USP 36-NF 31](#)

[USP 35-NF 30](#)

[USP 34-NF 29](#)

[USP 33-NF 28](#)

[USP 32-NF 27](#)

[USP 31-NF 26](#)

Interim Revision Announcements

IRAs published in 50(4)

- Dimethyl Fumarate Delayed-Release Capsules
- Protriptyline Hydrochloride

IRAs published in 50 (3)

- Methylprednisolone Acetate Injectable Suspension

IRAs published in 50(2)

No comments were received when the following proposals were published

- Gadopentetate Dimeglumine Injection

The following proposal have comments under consideration

- Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets

IRAs published in 50(1)

- [Commentary](#) (posted 28-Jun-2024)
 - Clonidine Transdermal System
 - Norgestimate

IRAs published in 49(6)

- [Commentary](#) (posted 26-Apr-2024)
 - Acyclovir

-
- Zinc Acetate
 - Zinc Chloride
 - Zinc Sulfate

IRAs published in 49(5)

- [Commentary](#) (posted 26-Jan-2024)
 - <64> Probiotic Tests
 - Lactobacillus acidophilus
 - Ligilactobacillus salivarius
- [Commentary](#) (posted 23-Feb-2024)
 - Sitigliptan Tablets

IRAs published in 49(4)

- [Commentary](#) (posted 26-Jan-2024)
 - Fosfomycin Tromethamine

IRAs published in 49(3)

No IRA proposals were published in PF 49(3)

- [Commentary](#) (posted 25-Aug-2023)
 - <660> Containers- Glass
 - <661.2> Plastic Packaging System for Pharmaceutical Use
- [Commentary](#) (posted 29-Sep-2023)
 - Phenoxybenzamine Hydrochloride

IRAs published in 49(2)

No comments were received when the following item was published:

- Bicalutamide Tablets

IRAs published in 49(1)

No IRA proposals were published in PF 49(1)

- [Commentary](#) (posted 26-May-2023)
 - Ziprasidone Hydrochloride

Previous PF Issues

Expand/collapse list

[Pharmacopeial Forum 48, Issues 1-6](#)

[Pharmacopeial Forum 47, Issues 1-6](#)

[Pharmacopeial Forum 46, Issues 1-6](#)

[Pharmacopeial Forum 45, Issues 1-6](#)